This activity is expired and is no longer available for CME credit.


Moving the Needle in Neovascular Age-related Macular Degeneration Treatment

Author(s)/Faculty: Michael S. Ip, MD; Peter K. Kaiser, MD
Release Date: 4/24/2020Expiration Date: 4/23/2021
Credit Type: CME / ABO MOCNumber of Credits: 0
Content Type: LectureProvider:
Intravitreal therapy has rapidly evolved to become a mainstay of treatment for many retinal diseases, offering patients delayed or arrested disease progression, with the possibility of regaining lost vision. The treatment of patients with neovascular age-related macular degeneration (nAMD) has been revolutionized by intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy. However, long-term extensions of major clinical trials have not demonstrated consistent success in maintaining the dramatic vision gains obtained initially, particularly when as-needed dosing was used. Fixed-interval or treat-and-extend protocols, which generally use more frequent injections, have had success in maintaining vision gains. Further, newer protocols that allow for longer intervals between treatments are now available and hold promise in lessening treatment burden. In this educational activity, expert faculty discuss the latest evidence-based medicine regarding treatment protocols for patients with nAMD.